HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Julio Rosenstock Selected Research

Exenatide (Byetta)

10/2021Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
10/2020Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
11/2019Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
1/2018Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
1/2018Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
1/2018Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
1/2018Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.
1/2018Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study.
5/2014Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
10/2013Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Julio Rosenstock Research Topics

Disease

185Type 2 Diabetes Mellitus (MODY)
01/2022 - 04/2002
56Hypoglycemia (Reactive Hypoglycemia)
01/2022 - 11/2003
50Body Weight (Weight, Body)
11/2022 - 02/2006
33Weight Loss (Weight Reduction)
11/2022 - 05/2005
23Weight Gain
06/2021 - 06/2004
18Nausea
10/2021 - 02/2006
15Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2022 - 01/2005
14Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 07/2015
12Overweight
11/2022 - 11/2003
12Vomiting
10/2021 - 01/2011
12Infections
01/2019 - 06/2012
11Heart Failure
08/2022 - 07/2012
9Obesity
11/2022 - 03/2005
8Kidney Diseases (Kidney Disease)
01/2022 - 09/2015
8Myocardial Infarction
10/2021 - 11/2016
8Stroke (Strokes)
10/2021 - 11/2016
8Hyperglycemia
01/2018 - 07/2010
7Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
01/2022 - 03/2015
6Pancreatitis
10/2021 - 01/2017
5Prediabetic State (Prediabetes)
08/2022 - 07/2010
5Insulin Resistance
01/2021 - 10/2006
5Diarrhea
01/2021 - 01/2011
5Albuminuria
04/2020 - 09/2015
5Urinary Tract Infections (Urinary Tract Infection)
01/2018 - 06/2012
4Chronic Renal Insufficiency
12/2021 - 01/2019
4Body Weight Changes
06/2021 - 02/2006
4Injection Site Reaction
11/2020 - 03/2013
4Diabetes Mellitus
01/2020 - 05/2002
4Edema (Dropsy)
07/2012 - 03/2006
3Pain (Aches)
11/2017 - 08/2004
3Neuralgia (Stump Neuralgia)
11/2017 - 09/2008
3Dizziness (Lightheadedness)
12/2014 - 08/2004
3Peripheral Nervous System Diseases (PNS Diseases)
02/2013 - 08/2004
2Proteinuria
09/2021 - 01/2021
2Constipation
01/2021 - 01/2011
2Cognitive Dysfunction
11/2020 - 10/2019
2Hypersensitivity (Allergy)
11/2020 - 03/2013

Drug/Important Bio-Agent (IBA)

75Insulin (Novolin)FDA Link
01/2022 - 04/2002
61Glucose (Dextrose)FDA LinkGeneric
01/2022 - 11/2003
57Metformin (Glucophage)FDA LinkGeneric
11/2020 - 05/2005
48Insulin Glargine (Lantus)FDA Link
01/2022 - 11/2003
23Glucagon-Like Peptide-1 ReceptorIBA
01/2022 - 10/2009
19lixisenatideIBA
01/2022 - 09/2013
19LinagliptinIBA
09/2021 - 08/2012
18Exenatide (Byetta)FDA Link
10/2021 - 05/2005
18Hypoglycemic Agents (Hypoglycemics)IBA
06/2021 - 10/2004
17Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2021 - 09/2002
16Glucagon-Like Peptide 1 (GLP 1)IBA
01/2022 - 07/2009
14Sodium-Glucose Transporter 2 InhibitorsIBA
01/2022 - 07/2012
14Sodium-Glucose Transport ProteinsIBA
01/2021 - 06/2012
14Pharmaceutical PreparationsIBA
01/2019 - 02/2006
13semaglutideIBA
11/2022 - 11/2016
12LiraglutideFDA Link
11/2022 - 07/2009
11empagliflozinIBA
08/2022 - 07/2014
11Glucagon-Like Peptide-1 Receptor AgonistsIBA
01/2022 - 04/2014
11LipidsIBA
03/2012 - 03/2005
9CreatinineIBA
01/2022 - 06/2012
8omega-Chloroacetophenone (Mace)IBA
10/2021 - 01/2019
8glimepiride (Amarel)FDA LinkGeneric
01/2021 - 08/2012
8dapagliflozinIBA
01/2020 - 07/2012
7InsulinsIBA
01/2022 - 04/2012
7AlbuminsIBA
01/2022 - 09/2015
7SodiumIBA
01/2022 - 07/2012
7Blood Glucose (Blood Sugar)IBA
01/2021 - 03/2010
7Dipeptidyl-Peptidase IV InhibitorsIBA
11/2020 - 01/2008
7Pioglitazone (Actos)FDA Link
11/2019 - 10/2006
7saxagliptinFDA Link
01/2019 - 11/2010
6LDL CholesterolIBA
01/2022 - 08/2008
6(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA
12/2021 - 07/2013
6rGLP-1 proteinIBA
11/2021 - 10/2009
6insulin degludecIBA
01/2021 - 03/2011
6CanagliflozinIBA
01/2019 - 06/2012
6Colesevelam Hydrochloride (Welchol)FDA Link
07/2012 - 08/2008
5efpeglenatideIBA
01/2022 - 01/2019
5Sitagliptin Phosphate (Januvia)FDA Link
01/2019 - 10/2006
52,4-thiazolidinedione (thiazolidinedione)IBA
01/2018 - 09/2002
4Protamines (Protamine Sulfate)FDA Link
06/2021 - 10/2004
4IncretinsIBA
01/2021 - 05/2005
4Hemoglobins (Hemoglobin)IBA
01/2019 - 07/2010
4LY2605541IBA
01/2014 - 11/2012
4ExuberaFDA Link
03/2010 - 06/2004
4PowdersIBA
03/2010 - 02/2007
3Insulin Aspart (NovoLog)FDA Link
06/2021 - 10/2004
3insulin aspart protamine drug combination 30:70 insulin aspartIBA
06/2021 - 10/2004
3SuspensionsIBA
10/2020 - 01/2008
3Insulin Lispro (Humalog)FDA Link
10/2020 - 01/2008
3insulin glulisineFDA Link
08/2016 - 10/2004
3Short-Acting InsulinIBA
01/2016 - 09/2013
3Isophane Insulin (NPH Insulin)FDA Link
11/2012 - 11/2004
3oxidized low density lipoproteinIBA
07/2012 - 07/2010
3VildagliptinIBA
01/2008 - 02/2007
2KetonesIBA
01/2022 - 12/2018
2tirzepatideIBA
10/2021 - 01/2021
2Peptides (Polypeptides)IBA
10/2021 - 01/2021
2insulin icodecIBA
01/2021 - 11/2020

Therapy/Procedure

71Therapeutics
08/2022 - 09/2002
58Glycemic Control
01/2022 - 04/2002
15Injections
01/2022 - 04/2002
4Subcutaneous Injections
01/2021 - 04/2002
2Aftercare (After-Treatment)
01/2022 - 12/2011